Learn About RSV Vaccine Information and Schedules

What RSV Is and Why a Vaccine Matters

Respiratory syncytial virus, or RSV, is a common virus that infects the lungs and breathing passages. Most people get RSV at least once in their lifetime, and many experience it multiple times throughout their lives. For many years, RSV was primarily known as a virus affecting infants and young children, causing symptoms like cough, congestion, and difficulty breathing. However, RSV also poses serious health risks to older adults and people with certain chronic conditions.

Get Your Free Roblox Private Server Guide →

The virus spreads through respiratory droplets when an infected person coughs or sneezes. It can also spread by touching contaminated surfaces and then touching your face. RSV typically causes mild cold-like symptoms in healthy adults, but in vulnerable populations, it can lead to severe lower respiratory tract disease, pneumonia, and hospitalization. According to the Centers for Disease Control and Prevention, RSV causes an estimated 60,000 to 160,000 hospitalizations annually in people aged 65 and older in the United States.

For decades, no vaccine existed for RSV, despite researchers understanding the virus since the 1950s. In 2023, the U.S. Food and Drug Administration approved the first RSV vaccines for adults, marking a significant advancement in disease prevention. These vaccines are designed to teach your immune system to recognize and fight RSV if you encounter it later. Understanding how RSV affects different age groups and why vaccination may matter for your health is the first step in making informed decisions about your health care.

Practical takeaway: RSV is a widespread respiratory virus with serious potential consequences for older adults and immunocompromised individuals. Learning about RSV vaccination options gives you information to discuss with your healthcare provider about whether a vaccine might fit your personal health situation.

FDA-Approved RSV Vaccines and How They Work

Currently, two RSV vaccines have received FDA approval for use in adults. GSK's Arexvy (RSV F vaccine recombinant) and Pfizer's Abrysvo (RSV prefusion F vaccine recombinant) both represent significant developments in RSV prevention. Both vaccines use recombinant technology, meaning they contain only a specific protein from the RSV virus—not the whole virus itself—which cannot cause RSV infection.

Free Guide to Understanding Grey Hair Prevention Options →

Arexvy is administered as a single dose injection in the upper arm muscle. Abrysvo is also administered as a single dose injection. Both vaccines work by stimulating your immune system to produce antibodies against the RSV F protein, which is the part of the virus responsible for infecting cells. When vaccinated individuals encounter the actual RSV virus, their immune system can recognize it and mount a faster, stronger response, potentially preventing severe illness or reducing the severity of symptoms.

Clinical trials demonstrated meaningful protection with both vaccines. In the Arexvy trial, the vaccine reduced the risk of RSV lower respiratory tract disease by approximately 82.6% in adults 60 years and older. In the Abrysvo trial for adults 60 and older, vaccine efficacy was approximately 81.6% against RSV lower respiratory tract disease. These percentages represent people in the trial who did not develop severe RSV disease during the study period compared to those who received a placebo injection.

Both vaccines are inactivated vaccines, meaning they cannot give you RSV. The vaccines use different formulations of the RSV F protein, but both aim to achieve similar protection. Your healthcare provider can discuss which vaccine might be more suitable based on your individual health situation, any allergies you may have, and other personal factors. Side effects from both vaccines are typically mild to moderate and may include arm soreness, fatigue, muscle aches, or headache lasting a few days.

Practical takeaway: Two different RSV vaccines are now available for adults. Both work similarly by training your immune system to recognize RSV, and both showed substantial protection against severe RSV disease in clinical trials. Understanding the basic mechanism of how these vaccines work can help you have a more informed conversation with your healthcare provider.

Vaccine Schedules and Age Considerations

As of 2024, RSV vaccines are recommended for adults aged 60 years and older, though specific recommendations continue to evolve as health agencies gather more data on vaccine effectiveness and safety. The CDC's recommendations also note that some adults aged 50 to 59 years with chronic conditions may benefit from RSV vaccination, and decisions should be made in consultation with a healthcare provider based on individual risk factors.

Learn How To Connect Headphones To Your Laptop →

Both approved RSV vaccines are single-dose vaccines, meaning you receive one injection and do not require a booster dose based on current recommendations. This differs from some other vaccines that require multiple doses or periodic boosters. The single-dose approach simplifies the vaccination schedule and makes it easier for individuals to complete their vaccination series. However, recommendations may change as long-term data become available regarding how long vaccine protection lasts.

For adults aged 60 and older, the RSV vaccine can be administered at any time of year. Unlike seasonal flu vaccines, timing does not follow a specific season-based schedule. However, many people choose to receive RSV vaccination during fall and winter months, when RSV transmission typically increases. RSV season in North America generally runs from October through March, with peak activity usually occurring in January and February. Getting vaccinated before peak season begins may offer practical advantages, though protection develops within two to four weeks after vaccination.

Your healthcare provider can discuss when vaccination makes sense in your personal circumstances. If you have upcoming surgery or other medical procedures, your provider might recommend timing your RSV vaccination to avoid administering it too close to other medical interventions. There are generally no restrictions on receiving RSV vaccine at the same time as other vaccines such as flu or COVID-19 vaccines, though injections should be given in different arms.

Practical takeaway: RSV vaccines are currently recommended for adults 60 and older as a single dose with no booster required under current guidance. You can receive the vaccine at any time, though fall and early winter may offer timing advantages. Discussing your personal health situation and when vaccination fits into your overall healthcare plan should happen in conversation with your doctor.

Who Should Consider RSV Vaccination

Adults aged 60 years and older represent the primary group for whom RSV vaccination is recommended. This age group experiences the highest risk of severe RSV disease, hospitalization, and complications. As people age, their immune system changes in ways that make it harder to fight off infections. Additionally, older adults are more likely to have chronic health conditions that further increase their risk of severe RSV disease.

Learn How Square Payment Processing Works →

Beyond age 60, certain individuals in younger age groups may also benefit from RSV vaccination. Adults aged 50 to 59 years who have chronic heart or lung disease, weakened immune systems, or other significant health conditions may be candidates for RSV vaccination. This includes people with conditions such as chronic obstructive pulmonary disease (COPD), asthma, heart disease, diabetes, or those living with HIV or taking immunosuppressive medications. People living in long-term care facilities, nursing homes, or assisted living environments also face higher risk because of the congregate living setting and potentially higher exposure to RSV.

Healthcare workers and caregivers may also consider RSV vaccination, though individual decisions should be based on discussion with their healthcare provider. People who work in healthcare settings or who provide care to infants, young children, or older adults face occupational exposure to RSV. Vaccinating healthcare workers and caregivers may reduce their risk of infection and lower the chance of transmitting RSV to vulnerable populations they work with or care for.

The CDC and other health organizations continue to gather data on RSV vaccine outcomes and may expand or refine recommendations over time. Some people may fall into categories where the decision to vaccinate requires conversation with their healthcare provider to weigh their individual risk factors, medical history, and other personal circumstances. This personalized approach to vaccination decisions reflects the understanding that vaccine recommendations work best when they account for each person's unique health situation.

Practical takeaway: RSV vaccination is primarily recommended for adults 60 and older. Adults aged 50 to 59 with chronic conditions, those in congregate living settings, and caregivers to vulnerable populations may also benefit from discussing vaccination with their healthcare provider. Your individual circumstances should guide conversations about whether RSV vaccination makes sense for you.

Side Effects and Safety Information

Both FDA-approved RSV vaccines underwent extensive testing in clinical trials involving tens of thousands of participants before receiving approval. Safety monitoring continues after approval through systems like the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink, which track any reported health events following vaccination to identify patterns

Get Your Free Dell Monitor Service Tag Guide →